Elon Musk is "confident" in the Neuralink technology and anticipates starting human trials in six months

 The Neuralink technology anticipates starting

The Neuralink technology anticipates starting

Elon Musk, the CEO of Tesla and Twitter, made a significant announcement regarding his business Neural ink's development of a brain chip on Wednesday.

The wireless device, which would be implanted in the brains of crippled patients in an effort to enable them to move and communicate once again, is anticipated to start human clinical trials in six months, according to the business magnate.

Testing & Approval

Since a few years ago, Neural ink has been testing its products on animals while awaiting regulatory approval from the US. Musk said Wednesday night in a public update on the device, "We want to be extremely careful and certain that it will work well before putting a device into a human, but we've submitted I think most of our paperwork to the FDA and probably in about six months we should be able to upload Neural ink in a human.

Device Ready for human use

A show-and-tell session for Neuralink that Musk was supposed to host was moved from October 31 to October 24 without a justification. After the update on Wednesday evening, Musk responded to a Bloomberg piece about the revelation on Twitter by saying the business is "now convinced" the device is prepared for use by people. Timing, he continued, "is dependent on moving through the FDA clearance process."

In April 2021, Neuralink gave its final public demonstration, which featured a monkey with an implanted chip using solely its brain to play a computer game.

Musk founded Neuralink in 2016 with the intention of creating a chip that would enable the brain to operate sophisticated technological equipment and, in the long run, allow paralyzed individuals to regain motor function.

Usages of Neuralink

If the technology is successful, it will use a brain chip to merge brain functions with artificial intelligence. According to Musk, it could aid in the treatment of conditions including Parkinson's, dementia, and Alzheimer's.

A bit late in the approval

Although Musk had hoped to have regulatory approval by the end of 2020, which was a goal of his in 2019, the firm is currently running a little behind schedule. Musk stated his intention to start human trials in 2022 during a meeting in late 2021.

According to Reuters, current and former Neuralink employees have also claimed that the business violated internal deadlines to obtain FDA approval to begin human trials.

Competitor company Synchron is also working on a microchip that would help patients with paralysis communicate through a brain-computer interface device.

The business implanted its device in a patient in the United States for the first time in July 2021 after receiving FDA approval in the summer of 2021. According to Reuters, Synchron has also finished its studies on four Australian subjects.

According to prior Fox Business reports, Musk approached his rival earlier this year about investment opportunities after the latter expressed frustration over Neuralink's sluggish development.

Courtesy Fox Business

Post a Comment


Research and Reviews| Finance, economics, reviews, analyses, banks, and political economy are among the topics. ...
Verification: 0a33a83c7e367e3b